Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 30:2020:4732021.
doi: 10.1155/2020/4732021. eCollection 2020.

Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis

Shu-Ying Li  1 , Ya-Ling Zhao  1 , Yu-Fan Yang  1 , Xi Wang  1 , Min Nie  1 , Xue-Yan Wu  1 , Jiang-Feng Mao  1
Affiliations

Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis

Shu-Ying Li et al. Int J Endocrinol. .

Abstract

Background: Testosterone replacement therapy (TRT) is commonly used for the treatment of hypogonadism in men, which is often associated with type 2 diabetes mellitus (T2DM) and metabolic syndrome (Mets). Recent compiling evidence shows that TRT has beneficial metabolic effects on these patients.

Objective: A meta-analysis has been conducted to evaluate the effects of TRT on cardiovascular metabolic factors.

Methods: We conducted a systemic search on PubMed, Embase, Cochrane Library, Wanfang, and CNKI and selected randomized controlled trials (RCTs) to include. The efficacy of TRT on glycemia, insulin sensitivity, lipid profile, and body weight was meta-analyzed by Review Manager.

Results: A total of 18 RCTs, containing 1415 patients (767 in TRT and 648 in control), were enrolled for the meta-analysis. The results showed that TRT could reduce HbA1c (MD = -0.67, 95% CI -1.35, -0.19, and P=0.006) and improve HOMA-IR (homeostatic model assessment of insulin resistance) (SMD = -1.94, 95% CI -2.65, -1.23, and P < 0.0001). TRT could also decrease low-density lipoprotein (SMD = -0.50, 95% CI -0.82, -0.90, and P=0.002) and triglycerides (MD = -0.64, 95% CI -0.91, -0.36, and P < 0.0001). In addition, TRT could reduce body weight by 3.91 kg (MD = -3.91, 95% CI -4.14, -3.69, and P < 0.00001) and waist circumference by 2.8 cm (MD -2.80, 95% CI -4.38, -1.21 and P=0.0005). Erectile dysfunction (measured by IIEF-5) did not improve, while aging-related symptoms (measured by AMS scores) significantly improved.

Conclusions: TRT improves glycemic control, insulin sensitivity, and lipid parameters in hypogonadism patients with T2DM and MetS, partially through reducing central obesity.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart summarizing the screening strategy for studies included for meta-analysis.
Figure 2
Figure 2
Risk bias assessment.
Figure 3
Figure 3
TRT results in increased HbA1c reduction compared to the control group.
Figure 4
Figure 4
TRT significantly improves HOMA-IR.
Figure 5
Figure 5
TRT can reduce LDLc.
Figure 6
Figure 6
TRT can reduce BMI.
Figure 7
Figure 7
Publication bias was evaluated by the change of HbA1c after TRT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bhasin S., Brito J. P., Cunningham G. R., et al. Testosterone therapy in men with hypogonadism: an endocrine society∗ clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):p. 1715. doi: 10.1210/jc.2018-00229. - DOI - PubMed
    1. Rabijewski M., Papierska L., Zgliczyński W., Piątkiewicz P. The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in polish population. Biomed Research International. 2013;2013:6. doi: 10.1155/2013/767496.767496 - DOI - PMC - PubMed
    1. Hall S. A., Esche G. R., Araujo A. B., et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. The Journal of Clinical Endocrinology & Metabolism. 2008;93(10):p. 3870. doi: 10.1210/jc.2008-0021. - DOI - PMC - PubMed
    1. Dhindsa S., Miller M. G., McWhirter C. L., et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):p. 1186. doi: 10.2337/dc09-1649. - DOI - PMC - PubMed
    1. Rabijewski M., Papierska L., Piątkiewicz P. Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population. The Aging Male. 2015;18(1):p. 16. doi: 10.3109/13685538.2015.1004048. - DOI - PubMed

LinkOut - more resources